CI=confidence interval; DTaP=diphtheria, tetanus, and acellular pertussis.
*The mean length of follow-up was 17 months, beginning 30 days after the third dose of vaccine.
†Typical pertussis as defined by the World Health Organization (WHO), 21 days or more of paroxysmal cough with infection confirmed by culture and/or serologic testing.2
‡Clinically milder disease with respect to type and duration of cough, with infection confirmed by culture and/or serologic testing.2
In an extended, unblinded follow-up period among children 3 to 6 years, the efficacy of INFANRIX against typical pertussis was 86% (95% CI: 79-91). Thus, protection against pertussis in children administered 3 doses of INFANRIX in infancy was sustained to 6 years of age.1,2
PEDIARIX is approved for use as a 3-dose primary series and by itself does not constitute a complete vaccination course for DTaP.1